EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer

Zhishan Chen, Han Jiang, Qingqing Qin, Qiyuan Li, Liqing Hong

Frontiers in Genetics · 06.06.2024 · 15

DOI: 10.3389/fgene.2024.1403907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 06.06.2024. Verfasst von Zhishan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Nan'an Hospital, Quanzhou, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BRCA) is one of the most common malignant tumors affecting women worldwide. DNA methylation modifications can influence oncogenic pathways and provide potential diagnostic and therapeutic targets for precision oncology. In this study, we used non-parametric permutation tests to identify differentially methylated positions (DMPs) between paired tumor and normal BRCA tissue samples from the Cancer Genome Atlas (TCGA) database. Then, we applied non-negative matrix factorization (NMF) to the DMPs to derive eight distinct DNA methylation signatures. Among them, signatures Hyper-S3 and Hypo-S4 signatures were associated with later tumor stages, while Hyper-S1 and Hypo-S3 exhibited higher methylation levels in earlier stages. Signature Hyper-S3 displayed an effect on overall survival. We further validated the four stage-associated signatures using an independent BRCA DNA methylation dataset from peripheral blood samples. Results demonstrated that 24 commonly hypomethylated sites in Hypo-S4 showed lower methylation in BRCA patients compared to healthy individuals, suggesting its potential as an early diagnostic biomarker. Furthermore, we found that methylation of 23 probes from four stage-related signatures exhibited predictive power for immune therapy response. Notably, methylation levels of all three probes from the Hypo-S4 and activity of the Hypo-S4 demonstrated highly positive relevance to PD-L1 gene expression, implying their significant predictive values for immunotherapy outcomes. GO and KEGG pathway enrichment analysis revealed that genes with these 23 immunotherapy-related methylation probes are mainly involved in glycan degradation or protein deglycosylation. These methylation signatures and probes may serve as novel epigenetic biomarkers for predicting tumor immunotherapy response. Our findings provide new insights into precision oncology approaches for BRCA.

Schlagwörter

Stichwörter der Autor:innen

DNA methylationbreast cancerimmune therapyprognosissignature

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, Nan'an Hospital, Quanzhou, China.
  • Department of General Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • School of Medicine, Xiamen University, Xiamen, China.

Zitieren

APA

Chen, Z., Jiang, H., Qin, Q., Li, Q., & Hong, L. (2024). DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer. Frontiers in Genetics, 15. https://doi.org/10.3389/fgene.2024.1403907

Vancouver

Chen Z, Jiang H, Qin Q, Li Q, Hong L. DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer. Frontiers in Genetics. 2024;15. doi:10.3389/fgene.2024.1403907

BibTeX
@article{Chen2024,
  author = {Chen, Zhishan and Jiang, Han and Qin, Qingqing and Li, Qiyuan and Hong, Liqing},
  title = {DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer},
  journal = {Frontiers in Genetics},
  year = {2024},
  volume = {15},
  doi = {10.3389/fgene.2024.1403907}
}
Kostenlos starten →